Comparative study of cilostazol that influence cerebral blood flow velocity and outcome in subarachnoid hemorrhage patients

Comparative study of cilostazol that influence cerebral blood flow velocity and outcome in subarachnoid hemorrhage patients - Influence of cilostazol on CBF and outcome in SAH

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024417

Enrollment

Registered

2016-10-16

Start date

2015-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

subarachnoid hemorrhage

Interventions

Intake of Cilostazol (200mg per day) Intake oflactose (200mg per day)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Aneurysmal subarachnoid patients

Exclusion criteria

Exclusion criteria: Non-aneurysmal subarachnoid hemorrhage

Design outcomes

Primary

Measure	Time frame
Cerebral blood flow velocity and cerebral blood flow volume calculated by preoperative and postoperative (day 7 to 11) cerebral angiography. Clinical outcome at day 30 and 90 after aneurysm rupture.	—

Secondary

Measure	Time frame
Incidence and severity of cerebral vasospasm	—

Countries

Japan

Contacts

Public ContactNorihito Shimamura

Hirosaki University Graduate School of Medicine Department of Neurosurgery

shimab@hirosaki-u.ac.jp0172-39-5115

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026